GlobeNewswire Inc.··Aclaris Therapeutics, Inc.Aclaris to Present Phase 2a ATI-2138 Data at 2026 AAD Meeting
Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.
ACRSclinical trial resultsatopic dermatitis